<?xml version="1.0" encoding="UTF-8"?>
<p id="par0030">Remdesivir, a nucleotide analogue prodrug with broad-spectrum antiviral activity (
 <xref rid="bib0065" ref-type="bibr">Sheahan et al., 2017</xref>, 
 <xref rid="bib0055" ref-type="bibr">Mulangu et al., 2019</xref>), has shown promising activity against SARS-CoV-2 in vitro (
 <xref rid="bib0070" ref-type="bibr">Wang et al., 2020a</xref>). Two case reports (
 <xref rid="bib0035" ref-type="bibr">Holshue et al., 2020</xref>, 
 <xref rid="bib0040" ref-type="bibr">Kujawski et al., 2020</xref>) and a recent clinical study of 54 patients (
 <xref rid="bib0030" ref-type="bibr">Grein et al., 2020</xref>) showed encouraging results in COVID-19 patients. Conversely, a randomized study did not show any significant clinical benefit, although it probably lacked power (
 <xref rid="bib0075" ref-type="bibr">Wang et al., 2020b</xref>).
</p>
